Summary & Overview
HCPCS J7187: Von Willebrand Factor Complex (Humate-P) Injection, per IU
HCPCS Level II code J7187 identifies the injectable von Willebrand factor complex product Humate‑P, billed per international unit of von Willebrand factor activity. This pharmacologic replacement therapy is used in the management of von Willebrand disease and related bleeding disorders; accurate coding supports appropriate billing and tracking of biologic utilization nationally. The code matters because von Willebrand factor products are high-cost specialty biologics with implications for coverage policy, utilization management, and outpatient infusion resources.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of clinical context for use of J7187, expected sites of service, and the payer landscape relevant to coverage and billing. The publication outlines benchmarks and policy considerations typically associated with high-cost injectable replacement therapies, summarizes common billing modifiers and practical coding considerations, and highlights areas where payers often apply utilization controls.
The piece provides practical reference material for revenue cycle, pharmacy, and clinical teams: what J7187 describes, where the service is commonly delivered, and which payers are most frequently involved. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J7187 represents an injection of von Willebrand factor complex (Humate-P), billed per international unit of von Willebrand factor ristocetin cofactor activity (per iu vwf:rco). This code denotes the pharmaceutical product and dosing unit used for replacement therapy in patients with von Willebrand disease.
-
Service type: Injectable biologic replacement therapy
-
Typical site of service: Hospital outpatient infusion center, ambulatory infusion center, or other infusion settings where intravenous biologic replacement therapies are administered
Clinical & Coding Specifications
Clinical Context
A 28-year-old woman with von Willebrand disease type 2A presents to an outpatient hematology infusion center for treatment prior to a minor surgical procedure (dental extraction). She has a history of mucocutaneous bleeding and laboratory-confirmed low von Willebrand factor activity. The treating hematologist orders von Willebrand factor concentrate, dosed in international units of VWF:RCo, to raise factor levels peri-procedurally. The patient arrives at the outpatient infusion suite; nursing performs pre-infusion vital signs, confirms weight and prior factor dosing, obtains intravenous access, and verifies product lot and dose. The pharmacist compounds J7187 (humate‑P) per ordered IU of VWF:RCo and documents product lot, expiration, and measured IU. The nurse administers the intravenous infusion, monitors for infusion reactions for 30–60 minutes, records the exact IU administered, and updates the electronic medical record with infusion start/stop times and lot number. Post-infusion, the patient is observed for hemostasis and discharged with follow-up instructions and documentation of dose given for billing and audit purposes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no special modifier applies to the service |